The remarkable efficacy of mRNA based COVID-19 vaccines has sparked innovation and progress in mRNA based treatments, expanding their potential expressions towards broad spectrum of diseases.
The global mRNA vaccine and therapeutics market size for Covid-19 is estimated to be worth US$9 billion in 2024. Further, mRNA vaccine and therapeutics market size for other indications is projected to be US$1.99 billion by 2035, representing a CAGR of 16% during the forecast period from 2026 to 2035.
Majority of the clinical trials are focused on evaluating mRNA drug candidates intended for the treatment of infectious diseases (63%), followed by those targeting oncological disorders (18%).Several Investors, Having Realized the Opportunity Within This Upcoming Segment, Have Invested Over USD 11 Billion Across Various Funding Rounds Since 2013
We came across more than 100 funding instances focused on mRNA vaccine and therapeutics.
It is worth highlighting that the maximum number (31) of funding instances were reported in 2020, followed by 2021 (20). 
Notably, companies engaged in the mRNA therapeutics and vaccines domain have raised significant capital through venture capital financing (33%).
In addition, Bill & Melinda Gates Foundation emerged as the most active investor (in terms of number of instances) in this domain having participated in seven funding instances.
mRNA Vaccine and Therapeutics: Market Sizing and Opportunity Analysis
Using our proprietary methodology, we have provided informed projections, describing the historical trends and likely growth opportunity associated with the mRNA vaccine and therapeutics market. As per the base case forecast scenario, the market for other indications is estimated to grow at an annualized rate of 26%, during the period 2025 to 2035.
Leading Players in mRNA Vaccine and Therapeutics Market 
Examples of key companies engaged in the development of mRNA vaccine and mRNA therapeutics (which have also been profiled in this market report; the complete list of companies is available in the full report) include Arcturus Therapeutics, BioNTech, CureVac, Ethris, IMMORNA, Moderna, Providence Therapeutics, RNACure, Suzhou Abogen Biosciences and Turn Biotechnologies.

Distribution by Application Area -Covid-19 and Other Indications
Target Disease Indication -Influenza, Respiratory Syncytial Virus Infection and Cytomegalovirus Diseases

Geographical Regions (North America, Europe, Asia-Pacific, Latin America and Rest of the World)

Till date, four mRNA-based vaccines have received approval for the treatment of COVID-19, while a number of such candidates are being evaluated as potential therapies. Moreover, the overall success of the mRNA-based therapies and vaccines against COVID-19 has attracted the interest of several investors, specifically towards small and emerging mRNA focused biotechnology companies.
The Remarkable Success Of mRNA -Based Covid-19 Vaccines, Coupled with An Expanding Product Pipeline, Has Catalyzed Innovation and Advancements Of mRNA-Based Therapies Across a Wide Spectrum of Diseases.
Messenger ribonucleic acid (mRNA) is a type of single-stranded ribonucleic acid (RNA), which helps in transferring genetic information in order to produce proteins. The mRNA encoding instructions for protein synthesis are transferred from a strand of DNA to the ribosomes, where these instructions are translated and processed into functional proteins. mRNA therapeutics and mRNA vaccines have emerged as a promising alternative to conventional treatment approaches. Post the onset of the COVID-19 pandemic, mRNA therapeutics and mRNA vaccines have garnered significant attention as they have evolved as a revolutionary drug class for the treatment of COVID-19, as well as several other diseases, such as infectious diseases, cancer, genetic disorders and other disorders.
The success of mRNA-based therapeutics and vaccines has increased the research activity in novel / next generation RNA therapeutics market. The rich pipeline of mRNA-based therapeutics and vaccines are also driving growth in the mRNA synthesis and manufacturing market, as the drug developers are seeking contract services to scale-up the manufacturing of mRNA-based drugs.
We identified majority of the mRNA vaccine and therapeutics are being enclosed in lipid nanoparticles for delivery inside the cells. It is worth mentioning that lipid nanoparticles have proved to be a versatile mRNA drug delivery system by playing a significant role in transporting the mRNA to the target cells effectively. Other commonly employed delivery methods for the mRNA vaccine and therapeutics include lipopolyplex and liposomes systems.
It is worth mentioning the market in North America is likely to capture majority (90%) of the overall share, and this trend is unlikely to change in the future, as well. This can be attributed to the high prevalence of infectious diseases in the US and Canada.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.  
To view more details on this report, click on the link 
https://www.rootsanalysis.com/reports/mrna-therapeutics-and-vaccines-market.html
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.		

We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.

Contact:
Roots Analysis 
+1 (415) 800 3415
Sales@rootsanalysis.com